Search results
Results From The WOW.Com Content Network
The rapid plasma reagin test (RPR test or RPR titer) is a type of rapid diagnostic test that looks for non-specific antibodies in the blood of the patient that may indicate an infection by syphilis or related non-venereal treponematoses. It is one of several nontreponemal tests for syphilis (along with the Wassermann test and the VDRL test).
Centers for Disease Control and Prevention (CDC)-approved standard tests include the VDRL test (a slide test), the rapid plasma reagin (RPR) test (a card test), the unheated serum reagin (USR) test, and the toluidine red unheated serum test (TRUST). [2] These have mostly replaced the first nontreponemal test, the Wassermann test. [citation needed]
The Venereal Disease Research Laboratory test (VDRL) is a blood test for syphilis and related non-venereal treponematoses that was developed by the eponymous US laboratory. The VDRL test is used to screen for syphilis (it has high sensitivity ), whereas other, more specific tests are used to diagnose the disease.
The Wassermann test or Wassermann reaction (WR) [1] is an antibody test for syphilis, named after the bacteriologist August Paul von Wassermann, based on complement fixation. It was the first blood test for syphilis and the first in the nontreponemal test (NTT) category. Newer NTTs, such as the RPR and VDRL tests, have mostly
The ground breaking for the hospital was July 10, 1984. It was completed January 16, 1990 but a water main break delayed the opening until July 9, 1990, when the first patient was admitted.The hospital treats cancer, and conducts research in the Solove Research Institute.
Treatment at this stage solely limits further progression of the disease and has a limited effect on damage which has already occurred. [3] Serologic cure can be measured when the non-treponemal titers decline by a factor of 4 or more in 6–12 months in early syphilis or 12–24 months in late syphilis. [21]
A 2010 review study by Puren et al. [2] categorizes viral load testing into three types: (1) nucleic acid amplification based tests (NATs or NAATs) commercially available in the United States with Food and Drug Administration (FDA) approval, or on the market in the European Economic Area (EEA) with the CE marking; (2) "Home–brew" or in-house NATs; (3) non-nucleic acid-based test.
This test tells whether there are antibodies in the maternal plasma. If positive, the antibody is identified and given a titer. Critical titers are associated with significant risk of fetal anemia and hydrops. [14] Titers of 1:8 or higher is considered critical for Kell. Titers of 1:16 or higher are considered critical for all other antibodies.